Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 4:26 pm Purchase | 2025-06-30 | 13G | Revolution Medicines, Inc. RVMD | Baker Bros. Advisors LP | 9,364,972 5.000% | 9,364,972 (New Position) | Filing History |
| 2025-08-14 4:26 pm Sale | 2025-06-30 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 12,903,708 6.800% | -6,593,495 (-33.82%) | Filing History |
| 2025-08-01 5:41 pm Purchase | 2025-08-01 | 13D | Celcuity Inc. CELC | Baker Bros. Advisors LP | 7,745,692 18.900% | 3,487,957 (+81.92%) | Filing History |
| 2025-06-30 8:26 pm Purchase | 2025-06-26 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 6,666,540 9.500% | 665,278 (+11.09%) | Filing History |
| 2025-06-13 5:21 pm Purchase | 2025-06-12 | 13D | Prelude Therapeutics Incorporated PRLD | Baker Bros. Advisors LP | 10,269,968 23.500% | 47,000 (+0.46%) | Filing History |
| 2025-05-15 4:33 pm Sale | 2025-03-31 | 13G | Candel Therapeutics, Inc. CADL | Baker Bros. Advisors LP | 2,455,108 4.990% | -526,875 (-17.67%) | Filing History |
| 2025-05-15 4:19 pm Purchase | 2025-03-31 | 13G | Neurogene Inc. NGNE | Baker Bros. Advisors LP | 1,486,313 9.960% | 836,628 (+128.77%) | Filing History |
| 2025-05-15 4:19 pm Sale | 2025-03-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | Baker Bros. Advisors LP | 5,604,483 8.900% | -793,882 (-12.41%) | Filing History |
| 2025-04-07 7:04 pm Purchase | 2025-03-31 | 13G | Celcuity Inc. CELC | Baker Bros. Advisors LP | 4,257,735 11.300% | 1,579,182 (+58.96%) | Filing History |
| 2025-03-31 7:35 pm Purchase | 2025-03-27 | 13D | DBV Technologies S.A. DBVT | Baker Bros. Advisors LP | 23,489,663 17.100% | 23,489,663 (New Position) | Filing History |
| 2025-03-07 5:07 pm Unchanged | 2025-03-07 | 13D | Replimune Group, Inc. REPL | Baker Bros. Advisors LP | 11,045,336 14.300% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:33 pm Purchase | 2025-02-12 | 13D | Sera Prognostics, Inc. SERA | Baker Bros. Advisors LP | 5,498,170 16.100% | 63,771 (+1.17%) | Filing History |
| 2025-02-14 4:16 pm Purchase | 2024-12-31 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 7,275,830 6.000% | 1,436,977 (+24.61%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Celcuity Inc. CELC | Baker Bros. Advisors LP | 2,678,553 7.200% | 803,575 (+42.86%) | Filing History |
| 2025-02-14 4:14 pm Purchase | 2024-12-31 | 13G | Candel Therapeutics, Inc. CADL | Baker Bros. Advisors LP | 2,981,983 6.800% | 2,981,983 (New Position) | Filing History |
| 2025-02-14 4:12 pm Sale | 2024-12-31 | 13G | Biomea Fusion, Inc. BMEA | Baker Bros. Advisors LP | 1,451,990 4.000% | -656,959 (-31.15%) | Filing History |
| 2024-12-31 4:18 pm Purchase | 2024-12-29 | 13D | KALA BIO, Inc. KALA | Baker Bros. Advisors LP | 1,201,894 19.700% | 310,559 (+34.84%) | Filing History |
| 2024-12-17 6:46 pm Purchase | 2024-12-13 | 13D | Bicycle Therapeutics plc BCYC | Baker Bros. Advisors LP | 10,885,357 22.900% | 1,485,397 (+15.80%) | Filing History |
| 2024-12-10 9:30 pm Sale | 2024-12-09 | 13D | BeOne Medicines Ltd. ONC | Baker Bros. Advisors LP | 125,276,610 13.000% | -13,401,427 (-9.66%) | Filing History |
| 2024-11-14 4:27 pm Purchase | 2024-09-30 | 13G | Sagimet Biosciences Inc. SGMT | Baker Bros. Advisors LP | 1,538,489 4.990% | 81,971 (+5.63%) | Filing History |